HUE038445T2 - TACI-IG fúziós fehérje, például atacicept alkalmazása lupusz eritomatózusz kezelésére szolgáló gyógyszer elõállítására - Google Patents

TACI-IG fúziós fehérje, például atacicept alkalmazása lupusz eritomatózusz kezelésére szolgáló gyógyszer elõállítására

Info

Publication number
HUE038445T2
HUE038445T2 HUE08771043A HUE08771043A HUE038445T2 HU E038445 T2 HUE038445 T2 HU E038445T2 HU E08771043 A HUE08771043 A HU E08771043A HU E08771043 A HUE08771043 A HU E08771043A HU E038445 T2 HUE038445 T2 HU E038445T2
Authority
HU
Hungary
Prior art keywords
atacicept
taci
medicament
manufacture
fusion protein
Prior art date
Application number
HUE08771043A
Other languages
English (en)
Inventor
Sharon J Busby
Jane A Gross
Jennifer Visich
Ivan Nestorov
Alain Munafo
Orestis Papasouliotis
Rossi Claudia Pena
Original Assignee
Zymogenetics Inc
Ares Trading Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics Inc, Ares Trading Sa filed Critical Zymogenetics Inc
Publication of HUE038445T2 publication Critical patent/HUE038445T2/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177Receptors; Cell surface antigens; Cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HUE08771043A 2007-06-13 2008-06-13 TACI-IG fúziós fehérje, például atacicept alkalmazása lupusz eritomatózusz kezelésére szolgáló gyógyszer elõállítására HUE038445T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94361807P 2007-06-13 2007-06-13
US2403108P 2008-01-28 2008-01-28

Publications (1)

Publication Number Publication Date
HUE038445T2 true HUE038445T2 (hu) 2018-10-29

Family

ID=40097164

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE08771043A HUE038445T2 (hu) 2007-06-13 2008-06-13 TACI-IG fúziós fehérje, például atacicept alkalmazása lupusz eritomatózusz kezelésére szolgáló gyógyszer elõállítására

Country Status (22)

Country Link
US (1) US20090186040A1 (hu)
EP (1) EP2167038B1 (hu)
JP (3) JP2010530000A (hu)
CN (2) CN105770891A (hu)
AU (1) AU2008265974B2 (hu)
CA (1) CA2690119A1 (hu)
CY (1) CY1120830T1 (hu)
DK (1) DK2167038T3 (hu)
EA (1) EA022911B1 (hu)
ES (1) ES2681195T3 (hu)
HR (1) HRP20181184T1 (hu)
HU (1) HUE038445T2 (hu)
IL (1) IL202305B (hu)
LT (1) LT2167038T (hu)
MX (1) MX2009013183A (hu)
PL (1) PL2167038T3 (hu)
PT (1) PT2167038T (hu)
SG (1) SG182191A1 (hu)
SI (1) SI2167038T1 (hu)
TR (1) TR201806960T4 (hu)
WO (1) WO2008157369A2 (hu)
ZA (1) ZA200908274B (hu)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103169966B (zh) * 2013-04-09 2015-04-01 中国人民解放军军事医学科学院基础医学研究所 一种治疗系统性红斑狼疮的药物组合物
EP3868403A4 (en) * 2019-12-24 2022-04-06 RemeGen Co., Ltd. TACI-FC FUSION PROTEIN AND USE THEREOF
TW202208414A (zh) * 2020-05-08 2022-03-01 美商艾爾潘免疫科學有限公司 April及baff抑制性免疫調節蛋白及其使用方法
CA3216795A1 (en) * 2021-05-07 2022-11-10 Alpine Immune Sciences, Inc. Methods of dosing and treatment with a taci-fc fusion immunomodulatory protein
CN117529506A (zh) * 2021-06-11 2024-02-06 海南先声药业有限公司 抗人il-17抗体和taci的双功能融合蛋白分子
WO2024114777A1 (zh) * 2022-12-02 2024-06-06 荣昌生物制药(烟台)股份有限公司 用TACI-Fc融合蛋白治疗微小病变型肾病的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2443437A1 (en) * 2001-05-18 2002-11-28 Boehringer Ingelheim International Gmbh Antibodies specific for cd44v6
AUPS057102A0 (en) * 2002-02-15 2002-03-07 Vri Biomedical Ltd Compositions and methods for treatment of skin disorders
US20050163775A1 (en) * 2003-06-05 2005-07-28 Genentech, Inc. Combination therapy for B cell disorders
RU2006117324A (ru) * 2003-10-20 2007-12-10 Байоджен Айдек Ма Инк. (Us) Терапевтические режимы для антагонистов baff
EA016083B1 (ru) * 2005-08-09 2012-02-28 Займоджинетикс, Инк. СПОСОБ ЛЕЧЕНИЯ НЕХОДЖКИНСКОЙ ЛИМФОМЫ С ПОМОЩЬЮ СЛИТОЙ МОЛЕКУЛЫ TACI-Ig
CN101489573B (zh) * 2006-05-15 2013-05-22 阿雷斯贸易股份有限公司 用TACI-Ig融合分子治疗自身免疫疾病的方法
WO2009082511A1 (en) * 2007-12-20 2009-07-02 Elc Management Llc Methods and compositions for treating skin

Also Published As

Publication number Publication date
EA200901630A1 (ru) 2010-06-30
EP2167038A2 (en) 2010-03-31
EA022911B1 (ru) 2016-03-31
CY1120830T1 (el) 2019-12-11
PT2167038T (pt) 2018-06-01
IL202305A0 (en) 2010-06-30
CN105770891A (zh) 2016-07-20
TR201806960T4 (tr) 2018-06-21
HRP20181184T1 (hr) 2018-09-21
SI2167038T1 (en) 2018-08-31
IL202305B (en) 2018-06-28
ZA200908274B (en) 2012-02-29
CA2690119A1 (en) 2008-12-24
AU2008265974A1 (en) 2008-12-24
JP2015013887A (ja) 2015-01-22
US20090186040A1 (en) 2009-07-23
LT2167038T (lt) 2018-05-25
WO2008157369A3 (en) 2009-02-19
PL2167038T3 (pl) 2018-10-31
AU2008265974A8 (en) 2010-01-07
EP2167038B1 (en) 2018-04-25
CN101790369A (zh) 2010-07-28
JP2017031209A (ja) 2017-02-09
JP2010530000A (ja) 2010-09-02
SG182191A1 (en) 2012-07-30
AU2008265974B2 (en) 2013-08-29
WO2008157369A2 (en) 2008-12-24
DK2167038T3 (en) 2018-08-06
ES2681195T3 (es) 2018-09-12
MX2009013183A (es) 2010-01-20

Similar Documents

Publication Publication Date Title
HRP20181184T1 (hr) Uporaba fuzijskog proteina taci-ig kao što je atacicept za proizvodnju lijeka za liječenje lupus eritematoze
PL1996292T3 (pl) Zastosowanie peptydów do kontroli obrażeń popromiennych
EP2117442A4 (en) SYSTEM FOR CONTROLLING A UNIVERSAL SURGICAL FUNCTION
GB0621310D0 (en) Medical needle safety devices
GB0500366D0 (en) Medical needle safety devices
GB0600212D0 (en) Medical needle safety device
EP2083680A4 (en) ACCEPTABLE IDENTIFIER WITH CONTROLLER ACTIVATION
PT2004636E (pt) Compostos de enaminocarbonilo substituídos utilizados como insecticidas
GB0724897D0 (en) Auto-injector
GB0710433D0 (en) Auto-injector
EP1997521A4 (en) MEDICAL MATERIAL
GB0719876D0 (en) Safety needle
HK1128237A1 (en) Further medical uses of antisecretory protein
EP2011530A4 (en) MEDICAL SAFETY SYRINGE WITH GRADUALLY SELF-RETRACTING NEEDLE
GB0715790D0 (en) Drug combination for the treatment of sialorrhoea
EP1999261A4 (en) USE OF PROTEIN S MELT FOR PROTEIN SOLUBILIZATION
GB2441430B (en) Safety hypodermic syringe
EP2191850A4 (en) TISSUE-CONNECTABLE MATERIAL FOR MEDICAL USE
HK1129861A1 (en) Use of peptides for the control of radiation injury
GB2437919B (en) Safety syringe
GB2445733B (en) Medical syringe
TWM300112U (en) Safety hypodermic syringe
GB0704952D0 (en) Medical needle saftey devices
GB2434538B (en) Safety syringe
EP2049176A4 (en) SYRINGE WITH ENHANCED SAFETY